Literature DB >> 203416

Vitamin D metabolism.

H F Deluca.   

Abstract

During the past decade, an explosion of information has become available on the metabolism and function of vitamin D which is of great importance to clinicians in the treatment of metabolic bone disease. We have learned that vitamin D is the precursor of at least one hormone and that this hormone carries out functions in calcium and phosphorus metabolism bringing about mineralization of bone on one hand, and the prevention of hypocalcaemic tetany on the other. It may also function in the prevention of such degenerative bone diseases as osteoporosis. An important analogue of this hormone, 1alpha-hydroxyvitamin D3 has been prepared and is used successfully in the treatment of a variety of clinical conditions. This presentation will summarize these findings and their possible implications in these metabolic bone diseases.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 203416     DOI: 10.1111/j.1365-2265.1977.tb03356.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Response of plasma 1,25-dihydroxyvitamin D in the human PTH(1-34) infusion test: an improved index for the diagnosis of idiopathic hypoparathyroidism and pseudohypoparathyroidism.

Authors:  R Miura; S Yumita; K Yoshinaga; Y Furukawa
Journal:  Calcif Tissue Int       Date:  1990-05       Impact factor: 4.333

2.  Effect of 1-alpha-hydroxyvitamin D3 on osteoporosis in rats induced by oophorectomy.

Authors:  J U Lindgren; T S Lindholm
Journal:  Calcif Tissue Int       Date:  1979-04-17       Impact factor: 4.333

3.  Thyrotropes in the pituitary are target cells for 1,25 dihydroxy vitamin D3.

Authors:  M Sar; W E Stumpf; H F DeLuca
Journal:  Cell Tissue Res       Date:  1980       Impact factor: 5.249

4.  Effects of 1 alpha-hydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3 on bone remodeling.

Authors:  K Galus; J Szymendera; A Zaleski; K Schreyer
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

5.  1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.

Authors:  Yasuteru Kondo; Takanobu Kato; Osamu Kimura; Tomoaki Iwata; Masashi Ninomiya; Eiji Kakazu; Masahito Miura; Takehiro Akahane; Yutaka Miyazaki; Tomoo Kobayashi; Motoyasu Ishii; Norihiro Kisara; Kumiko Sasaki; Haruo Nakayama; Takehiko Igarashi; Noriyuki Obara; Yoshiyuki Ueno; Tatsuki Morosawa; Tooru Shimosegawa
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.